Basilea gains European approval for antibiotic ceftobiprole
This article was originally published in Scrip
Executive Summary
Swiss pharma Basilea has received marketing authorization in Europe for its antibiotic ceftobiprole, used to treat hospital-acquired pneumonia (HAP) and community-acquired pneumonia (CAP).